Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | FADS1 | O60427 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.61 |
| ▸ | APP | P05067 | 3/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179800 | 1.00 | GAA (0.73) | GAAMAPTATMPKMYT1RET | |
| Metaquine SCHEMBL7205743 | 0.90 | FADS1 (0.71) | GAAMAPTATMFADS1CYP2D6 | |
| SCHEMBL2012878 | 0.85 | MAPT (1.00) | GAAMAPTATMCYP2D6CYP1A2 | |
| SCHEMBL30362771 | 0.85 | MAPT (1.00) | GAAMAPTATMCYP2D6CYP1A2 | |
| SCHEMBL5309628 | 0.84 | MAPT (0.74) | GAAMAPTATMFADS1CYP2D6 | |
| SCHEMBL19633680 | 0.84 | FADS1 (0.63) | GAAMAPTATMFADS1CYP2D6 | |
| SCHEMBL12786925 | 0.84 | PKMYT1 (0.67) | GAAMAPTATMPKMYT1RET | |
| SCHEMBL4751748 | 0.83 | APP (0.70) | GAAMAPTATMFADS1CYP2D6 | |
| SCHEMBL4882303 | 0.83 | EGFR (0.69) | PKMYT1RETFADS1GAKKMT2A | |
| SCHEMBL21346925 | 0.82 | CYP1A2 (0.66) | GAAMAPTATMFADS1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9284368-B2 | Substituted pyrazines as cadherin-11 inhibitors | GEORGETOWN UNIVERSITY (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8680095-B2 | Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-03-25 | — | — | US | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2513062-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | Institut National de la Santé et de la Recherche Médicale (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2011073322-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | GAA 4124/4885MAPT 1798/4885ATM 3268/4885 |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | GAA 4124/4885MAPT 1798/4885ATM 3268/4885 |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | APP, BACE1, PSEN1 | GAA 537/4885MAPT 20/4885ATM 2757/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | GAA 1929/4885MAPT 1384/4885ATM 2300/4885 |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | CDH1, ICAM1, S100A11 | GAA 4124/4885MAPT 1798/4885ATM 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.